The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rim, Chai Hong | - |
dc.contributor.author | Kim, Chul Yong | - |
dc.contributor.author | Yang, Dae Sik | - |
dc.contributor.author | Yoon, Won Sup | - |
dc.date.accessioned | 2021-09-02T21:23:52Z | - |
dc.date.available | 2021-09-02T21:23:52Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1179-1322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81020 | - |
dc.description.abstract | Purpose: Lymph node metastasis of hepatocellular carcinoma is categorized as advanced in Barcelona Clinic of Liver Cancer staging, and sorafenib is a sole treatment recommended. However, appliance of local treatment including external beam radiotherapy (EBRT) has not been uncommon. We performed a meta-analysis and systemically reviewed current literature to evaluate the efficacy and safety of EBRT. Methods: PubMed, Medline, Cochrane library, and Embase were systemically searched until December 17, 2017. The primary endpoint of analyses was response rate (RR), and 1-year overall survival and complication rates of grade >= 3 were secondary endpoints. Complications were primarily assessed descriptively. Results: A total of 8 studies comprising 521 patients were included. The pooled RR was 73.1% (95% confidence interval [CI]: 63.6-80.9), and high-dose EBRT groups had better RR than the low-dose group (82.2% [95% CI: 74.4-88.1] vs 51.1% [95% CI: 40.3-61.7]; P=0.001]. The pooled 1-year overall survival rate was 41.0% (95% CI: 32.9-49.6). Six studies assessed the survival benefit according to RR, and 5 (83.3%) of these 6 studies reported statistically significant survival benefit. The most common grade >= 3 toxicities were thrombocytopenia and gastrointestinal complication, with pooled rates of 3.4% (95% CI: 1.2-9.5) and 3.5% (95% CI: 1.7-7.2), respectively. Conclusion: EBRT showed a pooled RR of 73.1% and was safely performed. EBRT might palliate symptoms through tumor reductions and improve survival. Use of sorafenib combined or sequentially with EBRT can be recommended rather than monotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.subject | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject | IMAGE-GUIDED RADIOTHERAPY | - |
dc.subject | RADIATION-THERAPY | - |
dc.subject | EXTRAHEPATIC METASTASES | - |
dc.subject | TUMORS | - |
dc.subject | LYMPHADENECTOMY | - |
dc.subject | EPIDEMIOLOGY | - |
dc.subject | MANAGEMENT | - |
dc.subject | RESECTION | - |
dc.subject | BIAS | - |
dc.title | The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rim, Chai Hong | - |
dc.contributor.affiliatedAuthor | Kim, Chul Yong | - |
dc.contributor.affiliatedAuthor | Yang, Dae Sik | - |
dc.contributor.affiliatedAuthor | Yoon, Won Sup | - |
dc.identifier.doi | 10.2147/CMAR.S175703 | - |
dc.identifier.scopusid | 2-s2.0-85057596765 | - |
dc.identifier.wosid | 000443808700003 | - |
dc.identifier.bibliographicCitation | CANCER MANAGEMENT AND RESEARCH, v.10, pp.3305 - 3315 | - |
dc.relation.isPartOf | CANCER MANAGEMENT AND RESEARCH | - |
dc.citation.title | CANCER MANAGEMENT AND RESEARCH | - |
dc.citation.volume | 10 | - |
dc.citation.startPage | 3305 | - |
dc.citation.endPage | 3315 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject.keywordPlus | IMAGE-GUIDED RADIOTHERAPY | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | EXTRAHEPATIC METASTASES | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | LYMPHADENECTOMY | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | RESECTION | - |
dc.subject.keywordPlus | BIAS | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | lymph node metastasis | - |
dc.subject.keywordAuthor | meta-analysis | - |
dc.subject.keywordAuthor | radiation therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.